CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
We are very excited to launch our new website! Please take a few moments to click around and explore...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The new online Learning Center with new content can still be found under the “Training” folder on ...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...